1)大腸癌研究会(編).遺伝性大腸癌診療ガイドライン2020年版.金原出版,2020
2)Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 26:404-412, 2017
3)Chika N, Eguchi H, Kumamoto K, et al. Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 47:108-117, 2017
4)Yamamoto A, Yamaguchi T, Suzuki O, et al. Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population. Jpn J Clin Oncol 51:60-69, 2021
5)Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer(HNPCC, Lynch syndrome)proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453-1456, 1999
6)Vasen HFA. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 18(21 Suppl):81S-92S, 2000
7)Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome)and microsatellite instability. J Natl Cancer Inst 96:261-268, 2004
8)日本消化器病学会附置研究会がんゲノム医療時代におけるLynch症候群研究会.Lynch症候群について,2021 https://osaka-gs.jp/wp/wp-content/uploads/2021/08/Lynch症候群研究会.pdf(2023年10月30日閲覧)
9)Tsuruta T, Todo Y, Yamada R, et al. Initial screening by immunohistochemistry is effective in universal screening for Lynch syndrome in endometrial cancer patients:a prospective observational study. Jpn J Clin Oncol 52:752-758, 2022
10)Yamada A, Matsuoka Y, Minamiguchi S, et al. Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease. Mol Clin Oncol 15:247, 2021
11)Yamaguchi T. Screening for Lynch syndrome. In Tomita N(ed). Lynch Syndrome. Springer, pp 85-92, 2020
12)Chikatani K, Chika N, Suzuki O, et al. A model for predicting DNA mismatch repair-deficient colorectal cancer. Anticancer Res 40:4379-4385, 2020
13)Chung J, Negm L, Bianchi V, et al. Genomic microsatellite signatures identify germline mismatch repair deficiency and risk of cancer onset. J Clin Oncol 41:766-777, 2023
14)Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome:a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147:502-526, 2014
15)Heneghan HM, Martin ST, Winter DC. Segmental vs extended colectomy in the management of hereditary nonpolyposis colorectal cancer:a systematic review and meta-analysis. Colorectal Dis 17:382-389, 2015
16)SeppäläTT, Latchford A, Negoi I, et al. European guidelines from the EHTG and ESCP for Lynch syndrome:an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg 108:484-498, 2021
17)Cercek A, Lumish M, Sinopoli J, et al. PD-1 Blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386:2363-2376, 2022
18)Chikatani K, Chika N, Suzuki O, et al. Clinically applicable cases of anti-programmed cell death protein 1 immunotherapy for colorectal cancer patients. Surg Today 50:1694-1698, 2020
19)Hatamori H, Chino A, Arai M, et al. Malignant potential of colorectal neoplasms in Lynch syndrome:an analysis of 325 lesions endoscopically treated at a single institute. Jpn J Clin Oncol 51:737-743, 2021
20)Vasen HFA, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome(HNPCC):recommendations by a group of European experts. Gut 62:812-823, 2013
21)Dominguez-Valentin M, Haupt S, SeppäläTT, et al. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment:a report from the prospective Lynch syndrome database. EClinicalMedicine 58:101909, 2023
22)赤木究.Dial Studyグループ:リンチ症候群における臨床ゲノム情報統合データベースの構築(AMED事情).家族性腫瘍 19:13-14, 2019